These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16428039)

  • 41. Diagnosis and recognition of early esophageal neoplasia.
    Herszényi L; Pregun I; Tulassay Z
    Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry.
    Ganz RA; Overholt BF; Sharma VK; Fleischer DE; Shaheen NJ; Lightdale CJ; Freeman SR; Pruitt RE; Urayama SM; Gress F; Pavey DA; Branch MS; Savides TJ; Chang KJ; Muthusamy VR; Bohorfoush AG; Pace SC; DeMeester SR; Eysselein VE; Panjehpour M; Triadafilopoulos G;
    Gastrointest Endosc; 2008 Jul; 68(1):35-40. PubMed ID: 18355819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.
    Abela JE; Going JJ; Mackenzie JF; McKernan M; O'Mahoney S; Stuart RC
    Am J Gastroenterol; 2008 Apr; 103(4):850-5. PubMed ID: 18371135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas.
    Bollschweiler E; Baldus SE; Schröder W; Prenzel K; Gutschow C; Schneider PM; Hölscher AH
    Endoscopy; 2006 Feb; 38(2):149-56. PubMed ID: 16479422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting surveillance in Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1311-2. PubMed ID: 18853989
    [No Abstract]   [Full Text] [Related]  

  • 46. [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention].
    Peitz U; Malfertheiner P
    Z Gastroenterol; 2007 Dec; 45(12):1264-72. PubMed ID: 18080229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What's new in columnar lined esophagus (Barrett's metaplasia)?
    Tadiparthi R; Bansal A; Sharma P
    Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus.
    Tokar JL; Haluszka O; Weinberg DS
    Semin Radiat Oncol; 2007 Jan; 17(1):10-21. PubMed ID: 17185193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
    Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
    Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histology of metaplasia and dysplasia in Barrett's esophagus.
    Yerian L
    Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.
    Abraham SC; Krasinskas AM; Correa AM; Hofstetter WL; Ajani JA; Swisher SG; Wu TT
    Am J Surg Pathol; 2007 Nov; 31(11):1719-25. PubMed ID: 18059229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future developments in total Barrett's eradication: the surgeon's view.
    Watson TJ; Peters JH
    Endoscopy; 2008 Dec; 40(12):1048-51. PubMed ID: 19065490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoplastic precursor lesions in Barrett's esophagus.
    Hornick JL; Odze RD
    Gastroenterol Clin North Am; 2007 Dec; 36(4):775-96, v. PubMed ID: 17996790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
    Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
    J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Surgery of the upper gastrointestinal tract (part 1)].
    Fuchs KH
    Zentralbl Chir; 2003 Mar; 128(3):W20-30. PubMed ID: 12739517
    [No Abstract]   [Full Text] [Related]  

  • 60. Section II: pathology and pathologic staging of esophageal cancer.
    Glickman JN
    Semin Thorac Cardiovasc Surg; 2003 Apr; 15(2):167-79. PubMed ID: 12838487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.